Shandong Science ›› 2022, Vol. 35 ›› Issue (3): 17-26.doi: 10.3976/j.issn.1002-4026.2022.03.003
• Pharmacology and Toxicology • Previous Articles Next Articles
LI Xiao-li(
),YING Tian-hao,TANG Yi-di,ZHU Xuan,SUN Meng-meng,YU Tao,ZHAO Jia-ning,ZHANG Lei-ming*(
)
Received:2021-04-14
Published:2022-06-20
Online:2022-06-10
Contact:
Lei-ming ZHANG
E-mail:544123522@163.com;zhangleiming2009@126.com
CLC Number:
LI Xiao-li,YING Tian-hao,TANG Yi-di,ZHU Xuan,SUN Meng-meng,YU Tao,ZHAO Jia-ning,ZHANG Lei-ming. Potential mechanism of Mahuangjiazhu Decoction in the treatment of rheumatoid arthritis based on network pharmacology combined with molecular docking technology[J].Shandong Science, 2022, 35(3): 17-26.
Table 1
Active ingredients of Mahuangjiazhu Decoction by OB value (top 20)"
| 编号 | 活性成分 | 来源 | ||
|---|---|---|---|---|
| MOL002311 | Glycyrol(甘草酚) | 甘草、杏仁 | ||
| MOL012922 | l-SPD(左旋千金藤啶碱) | 杏仁 | ||
| MOL004990 | 7,2',4'-trihydroxy-5-methoxy-3-arylcoumarin(7,2',4'-三羟基-5-甲氧基-3-苯基香豆素) | 甘草 | ||
| MOL004904 | Licopyranocoumarin(甘草吡喃香豆素) | 甘草 | ||
| MOL004891 | Shinpterocarpin | 甘草 | ||
| MOL007207 | Machiline(乌药碱) | 杏仁 | ||
| MOL005017 | Phaseol | 甘草、杏仁 | ||
| MOL004841 | Licochalcone B(甘草查尔酮B) | 甘草、杏仁 | ||
| MOL004810 | glyasperin F(粗毛甘草素F) | 甘草 | ||
| MOL001484 | Inermine(高丽槐素) | 甘草 | ||
| MOL000500 | Vestitol(维斯体素) | 甘草 | ||
| MOL005007 | Glyasperins M(粗毛甘草素M) | 甘草 | ||
| MOL005190 | Eriodictyol(圣草酚) | 麻黄 | ||
| MOL004941 | (2R)-7-hydroxy-2-(4-hydroxyphenyl)chroman-4-one | 甘草 | ||
| MOL004959 | 1-Methoxyphaseollidin(1-甲氧基菜豆素) | 甘草 | ||
| MOL000392 | Formononetin(刺芒柄花素) | 甘草 | ||
| MOL003410 | Ziziphin_qt | 杏仁 | ||
| MOL004863 | 3-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-(3-methylbut-2-enyl)chromone | 甘草 | ||
| MOL004903 | Liquiritin(甘草苷) | 甘草、杏仁 | ||
| MOL004808 | glyasperin B(粗毛甘草素B) | 甘草 | ||
Table 2
Core target information"
| 靶点 | 靶点名称 | 度值 | 靶点 | 靶点名称 | 度值 |
|---|---|---|---|---|---|
| IL-6 | 白介素6 | 65 | MMP9 | 基质金属蛋白酶-9 | 42 |
| TNF | 肿瘤坏死因子 | 58 | EGF | 促表皮生长因子 | 41 |
| TP53 | 细胞肿瘤抗原 p53 | 55 | EGFR | 表皮生长因子受体 | 40 |
| STAT3 | 信号转导和转录激活因子3 | 55 | PTGS2 | 前列腺素内过氧化物合酶 2 | 40 |
| AKT1 | 蛋白激酶B | 54 | CCL2 | C-C趋化因子 2 | 39 |
| VEGFA | 血管内皮生长因子 A | 53 | RELA | 转录因子p65 | 39 |
| CXCL8 | 白介素8 | 50 | APP | 淀粉样前体蛋白 | 37 |
| JUN | c-Jun氨基末端激酶 | 50 | ICAM1 | 胞间黏附分子 1 | 37 |
| MAPK8 | 丝裂原活化蛋白激酶 8 | 49 | MYC | Myc原癌基因蛋白 | 36 |
| MAPK1 | 丝裂原活化蛋白激酶 1 | 48 | IL-10 | 白介素10 | 36 |
| IL-1β | 白介素1-β | 47 | SRC | 类固醇受体共激活因子 | 35 |
Table 3
Docking results of compounds in Mahuangjiazhu Decoction with top 10 targets sequencing in protein-protein interaction network"
| 活性成分 | 结合自由能/(kJ·mol-1) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AKT1 | PTGS2 | MAPK1 | MAPK8 | RELA | STAT3 | CXCL8 | IL1B | IL6 | TNF | |
| 槲皮素 | -9.5 | -9.6 | -8.4 | -7.6 | -7.3 | -7.3 | -6.6 | -7.0 | -7.1 | -6.7 |
| 木犀草素 | -9.5 | -9.4 | -8.4 | -8.1 | -6.9 | -7.8 | -6.5 | -6.8 | -7.0 | -6.2 |
| 山奈酚 | -9.5 | -9.7 | -8.2 | -7.5 | -7.3 | -7.0 | -6.7 | -6.7 | -6.7 | -6.3 |
| 柚皮素 | -9.6 | -9.1 | -7.9 | -7.6 | -7.0 | -7.7 | -6.3 | -6.9 | -6.8 | -6.4 |
| 刺芒柄花素 | -9.7 | -9.1 | -7.9 | -7.5 | -7.1 | -6.9 | -6.8 | -6.4 | -6.3 | -5.8 |
| 甘草酚 | -10.6 | -10.3 | -9.3 | -8.9 | -7.1 | -7.7 | -6.8 | -7.2 | -6.6 | -6.9 |
| 花旗松素 | -9.6 | -9.4 | -8.1 | -7.8 | -7.0 | -7.4 | -6.6 | -7.1 | -6.7 | -6.5 |
| (+)-儿茶素 | -9.9 | -9.2 | -8.5 | -8.8 | -7.5 | -7.4 | -7.2 | -7.7 | -7.3 | -7.3 |
| 甘草查尔酮 B | -9.5 | -8.5 | -7.4 | -7.2 | -6.6 | -6.6 | -6.0 | -6.4 | -6.2 | -5.8 |
| Phaseol | -11.2 | -10.2 | -9.4 | -9.0 | -7.7 | -8.1 | -7.0 | -7.3 | -7.7 | -7.3 |
| 光甘草定 | -9.7 | -8.4 | -8.0 | -8.8 | -8.6 | -7.7 | -6.8 | -7.5 | -7.3 | -6.4 |
| β-谷甾醇 | -10.8 | -8.3 | -9.1 | -8.7 | -6.9 | -7.9 | -6.9 | -7.7 | -7.3 | -7.0 |
| [1] |
LIU W, FAN Y H, TIAN C Y, et al. Deciphering the molecular targets and mechanisms of HGWD in the treatment of rheumatoid arthritis via network pharmacology and molecular docking[J]. Evidence Based Complementary and Alternative Medicine, 2020, 2020: 7151634. DOI: 10.1155/2020/7151634.
doi: 10.1155/2020/7151634 |
| [2] |
SPARKS J A. Rheumatoid arthritis[J]. Annals of Internal Medicine, 2019, 170(1): ITC1. DOI: 10.7326/aitc201901010.
doi: 10.7326/aitc201901010 |
| [3] |
RHEUMATOID A. Rheumatoid arthritis[J]. Nature Reviews Disease Primers, 2018, 4: 18002. DOI: 10.1038/nrdp.2018.2.
doi: 10.1038/nrdp.2018.2 |
| [4] |
FIRESTEIN G S, MCINNES I B. Immunopathogenesis of rheumatoid arthritis[J]. Immunity, 2017, 46(2): 183-196.DOI: 10.1016/j.immuni.2017.02.006.
doi: 10.1016/j.immuni.2017.02.006 |
| [5] |
ALETAHA D, SMOLEN J S. Diagnosis and management of rheumatoid arthritis: A review[J]. JAMA, 2018, 320(13): 1360-1372. DOI: 10.1001/jama.2018.13103.
doi: 10.1001/jama.2018.13103 |
| [6] |
van VOLLENHOVEN R. Treat-to-target in rheumatoid arthritis:are we there yet?[J]. Nature Reviews Rheumatology, 2019, 15(3): 180-186. DOI: 10.1038/s41584-019-0170-5.
doi: 10.1038/s41584-019-0170-5 |
| [7] |
RUTHERFORD A I, PATARATA E, SUBESINGHE S, et al. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis[J]. Rheumatology, 2018, 57(6): 997-1001. DOI: 10.1093/rheumatology/key023.
doi: 10.1093/rheumatology/key023 |
| [8] |
周春瑜, 陈艳林, 付庭娜, 等. 中医辨治类风湿关节炎的研究进展[J]. 风湿病与关节炎, 2020, 9(10): 72-75. DOI: 10.3969/j.issn.2095-4174.2020.10.020.
doi: 10.3969/j.issn.2095-4174.2020.10.020 |
| [9] |
徐茂林. 经方辨治类风湿性关节炎一得[J]. 国医论坛, 2007(1): 9-10. DOI: 10.3969/j.issn.1002-1078.2007.01.005.
doi: 10.3969/j.issn.1002-1078.2007.01.005 |
| [10] |
张瑞. 《金匮要略》痹病病因证治探析[J]. 中医研究, 2020, 33(12): 1-3.DOI: 10.3969/j.issn.1001-6910.2020.12.01.
doi: 10.3969/j.issn.1001-6910.2020.12.01 |
| [11] | 杜以梅. 经方在痹证治疗中的应用研究[D]. 南京: 南京中医药大学, 2007. |
| [12] |
张安东. 麻黄加术汤加味应用于风湿病的临床研究进展[J]. 光明中医, 2019, 34(23):3694-3696. DOI: 10.3969/j.issn.1003-8914.2019.23.065.
doi: 10.3969/j.issn.1003-8914.2019.23.065 |
| [13] | 邓慧芳. 基于源流梳理及名词考据的仲景微汗法应用阐释与实证研究[D]. 北京: 北京中医药大学, 2018. |
| [14] |
徐琦, 尹抗抗, 谭达全, 等. 麻黄加术汤对大鼠类风湿性关节炎模型作用机制的研究[J]. 湖南中医药大学学报, 2011, 31(5): 13-15. DOI: 10.3969/j.issn.1674-070X.2011.05.004.013.03.
doi: 10.3969/j.issn.1674-070X.2011.05.004.013.03 |
| [15] |
徐琦, 王红梅, 谭达全. 类风湿性关节炎患者外周血T细胞亚群经麻黄加术汤干预前后变化的研究[J]. 湖南中医杂志, 2014, 30(11): 157-159. DOI: 10.16808/j.cnki.issn1003-7705.2014.11.077.
doi: 10.16808/j.cnki.issn1003-7705.2014.11.077 |
| [16] |
解静, 高杉, 李琳, 等. 网络药理学在中药领域中的研究进展与应用策略[J]. 中草药, 2019, 50(10): 2257-2265. DOI: 10.7501/j.issn.0253-2670.2019.10.001.
doi: 10.7501/j.issn.0253-2670.2019.10.001 |
| [17] |
SHI X Q, YUE S J, TANG Y P, et al. A network pharmacology approach to investigate the blood enriching mechanism of Danggui buxue Decoction[J]. Journal of Ethnopharmacology, 2019, 235: 227-242. DOI: 10.1016/j.jep.2019.01.027.
doi: 10.1016/j.jep.2019.01.027 |
| [18] |
HSIN K Y, GHOSH S, KITANO H. Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology[J]. PLoS One. 2013, 8(12): e83922. DOI: 10.1371/journal.pone.0083922.
doi: 10.1371/journal.pone.0083922 |
| [19] |
葛高月, 郑新春. 类风湿关节炎中西医治疗进展[J]. 辽宁中医药大学学报, 2021, 23(2): 84-89. DOI: 10.13194/j.issn.1673-842x.2021.02.019.
doi: 10.13194/j.issn.1673-842x.2021.02.019 |
| [20] |
黄裕成. 麻黄加术汤治疗类风湿性关节炎的临床观察[J]. 光明中医, 2018, 33(5): 676-678. DOI: 10.3969/j.issn.1003-8914.2018.05.035.
doi: 10.3969/j.issn.1003-8914.2018.05.035 |
| [21] |
魏斐菲. 麻黄加术汤加味疗法治疗风湿病临床研究[J]. 亚太传统医药, 2017, 13(6):144-145. DOI: 10.11954/ytctyy.201706063.
doi: 10.11954/ytctyy.201706063 |
| [22] |
XUE H M, TU Y H, MA T, et al. Lactoferrin inhibits IL-1β-induced chondrocyte apoptosis through AKT1-induced CREB1 activation[J]. Cellular Physiology and Biochemistry, 2015, 36(6): 2456-2465. DOI: 10.1159/000430206.
doi: 10.1159/000430206 |
| [23] | ZHAO X Y, WANG T J, CAI B, et al. MicroRNA-495 enhances chondrocyte apoptosis, senescence and promotes the progression of osteoarthritis by targeting AKT1[J]. American Journal of Translational Research, 2019, 11(4): 2232-2244. |
| [24] |
MIYASHITA T, KAWAKAMI A, MAMI T M, et al. Akt is an endogenous inhibitor toward tumor necrosis factor-related apoptosis inducing ligand-mediated apoptosis in rheumatoid synovial cells[J]. Biochemical and Biophysical Research Communications, 2003, 312(2): 397-404.DOI: 10.1016/j.bbrc.2003.10.141.
doi: 10.1016/j.bbrc.2003.10.141 |
| [25] |
LIU H T, POPE R M. The role of apoptosis in rheumatoid arthritis[J]. Current Opinion in Pharmacology, 2003, 3(3): 317-322. DOI: 10.1016/S1471-4892(03)00037-7.
doi: 10.1016/S1471-4892(03)00037-7 |
| [26] |
DAI Q D, ZHOU D, XU L P, et al. Curcumin alleviates rheumatoid arthritis-induced inflammation and synovial hyperplasia by targeting mTOR pathway in rats[J]. Drug Design, Development and Therapy, 2018, 12: 4095-4105. DOI: 10.2147/DDDT.S175763.
doi: 10.2147/DDDT.S175763 |
| [27] |
YE Y, BAO C D, FAN W. Overexpression of miR-101 may target DUSP1 to promote the cartilage degradation in rheumatoid arthritis[J]. Journal of Computational Biology, 2019, 26(10): 1067-1079. DOI: 10.1089/cmb.2019.0021.
doi: 10.1089/cmb.2019.0021 |
| [28] |
范星宇, 洪梦琴, 杨敏. IL-6与类风湿关节炎的关系及作用机制的研究进展[J]. 世界最新医学信息文摘, 2019, 19(86): 65. DOI: 10.19613/j.cnki.1671-3141.2019.86.026.
doi: 10.19613/j.cnki.1671-3141.2019.86.026 |
| [29] |
REDLICH K, SMOLEN J S. Inflammatory bone loss: Pathogenesis and therapeutic intervention[J]. Nature Reviews Drug Discovery, 2012, 11(3): 234-250. DOI: 10.1038/nrd3669.
doi: 10.1038/nrd3669 |
| [30] |
WANG M L, LI H Y, WANG Y F, et al. Anti-rheumatic properties ofgentiopicroside are associated with suppression of ROS-NF-κB-NLRP3 axis in fibroblast-like synoviocytes and NF-κB pathway in adjuvant-induced arthritis[J]. Frontiers in Pharmacology, 2020, 11: 515. DOI: 10.3389/fphar.2020.00515.
doi: 10.3389/fphar.2020.00515 |
| [31] |
CHOW Y Y, CHIN K Y. The role of inflammation in the pathogenesis of osteoarthritis[J]. Mediators of Inflammation, 2020, 2020: 8293921. DOI: 10.1155/2020/8293921.
doi: 10.1155/2020/8293921 |
| [32] |
CHENG B C Y, FU X Q, GUO H, et al. The genus Rosa and arthritis: overview on pharmacological perspectives[J]. Pharmacological Research, 2016, 114: 219-234. DOI: 10.1016/j.phrs.2016.10.029.
doi: 10.1016/j.phrs.2016.10.029 |
| [33] | MILLERAND M, BERENBAUM F, JACQUES C. Danger signals andinflammaging in osteoarthritis[J]. Clinical and Experimental Rheumatology, 2019, 37(5): 48-56. |
| [34] |
BONAVENTURA P, LAMBOUX A, ALBARÈDE F, et al. Differential effects of TNF-α and IL-1β on the control of metal metabolism and cadmium-induced cell death in chronic inflammation[J]. PLoS One, 2018, 13(5): e0196285. DOI: 10.1371/journal.pone.0196285.
doi: 10.1371/journal.pone.0196285 |
| [35] |
HU X M, TANG J H, ZENG G, et al. RGS1 silencing inhibits the inflammatory response and angiogenesis in rheumatoid arthritis rats through the inactivation of Toll-like receptor signaling pathway[J]. Journal of Cellular Physiology, 2019, 234(11): 20432-20442. DOI: 10.1002/jcp.28645.
doi: 10.1002/jcp.28645 |
| [36] |
ARLEEVSKAYA M I, LARIONOVA R V, BROOKS W H, et al. Toll-like receptors, infections, and rheumatoid arthritis[J]. Clinical Reviews in Allergy & Immunology, 2020, 58(2): 172-181. DOI: 10.1007/s12016-019-08742-z.
doi: 10.1007/s12016-019-08742-z |
| [37] |
YUAN K, ZHU Q Q, LU Q Y, et al. Quercetin alleviates rheumatoid arthritis by inhibiting neutrophil inflammatory activities[J]. The Journal of Nutritional Biochemistry, 2020, 84: 108454. DOI: 10.1016/j.jnutbio.2020.108454.
doi: 10.1016/j.jnutbio.2020.108454 |
| [38] |
HOU Y N, WU J C, HUANG Q, et al. Luteolin inhibits proliferation and affects the function of stimulated rat synovial fibroblasts[J]. Cell Biology International, 2009, 33(2): 135-147.DOI: 10.1016/j.cellbi.2008.10.005.
doi: 10.1016/j.cellbi.2008.10.005 |
| [39] |
PAN D M, LI N, LIU Y Y, et al. Kaempferol inhibits the migration and invasion of rheumatoid arthritis fibroblast-like synoviocytes by blocking activation of the MAPK pathway[J]. International Immunopharmacology, 2018, 55: 174-182. DOI: 10.1016/j.intimp.2017.12.011.
doi: 10.1016/j.intimp.2017.12.011 |
|
||
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits third parties to freely share (i.e., copy and redistribute the material in any medium or format) and adapt (i.e., remix, transform, or build upon the material) the articles published in this journal, provided that appropriate credit is given, a link to the license is provided, and any changes made are indicated. The material may not be used for commercial purposes. For details of the CC BY-NC 4.0 license, please visit: https://creativecommons.org/licenses/by-nc/4.0